# A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Source: https://onco.cc/trials/nct06921837/  
OnCo record `nct06921837` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BDC-4182 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Bolt Biotherapeutics, Inc., now recruiting.

## Summary

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer is a phase 1/2 interventional study registered as NCT06921837 by Bolt Biotherapeutics, Inc., with 122 participants planned, started 2025-05-26 and due to reach its primary completion in 2027-05. Interventions recorded: BDC-4182.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06921837
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer
- Sponsor: Bolt Biotherapeutics, Inc.
- Enrolled: 122

## Sources

- ClinicalTrials.gov NCT06921837: https://clinicaltrials.gov/study/NCT06921837

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [BDC-4182](https://onco.cc/drugs/bdc-4182/)

---
JSON: https://onco.cc/api/v1/entities/nct06921837.json